News

New York based iBio, Inc. a biotech firm specializing in plant-based biotechnology for developing and manufacturing biological products and offering pharmaceutical product applications using its iBioLaunch platform, recently announced a new patent to aid in their development of a novel IPF therapy. The iBioLaunch gene expression platform is a…

Fibrocell Science, Inc., a company focused on autologous cell and gene therapy that is developing top treatments to address rare and life-threatening skin and connective tissue illnesses, has announced that it will report its first quarter 2015 results next Friday, May 8, 2015. The report will be made available to the public before the United States financial markets…

Researchers in Saudi Arabia at King Fahd Hospital of the University and the University of Dammam reported a case of a male patient with scleroderma who was diagnosed with an acute rare condition called central retinal vein occlusion (CRVO). The study was published in the…

A new study recently published in the journal Science revealed that a specific skin cell type is associated to wound healing and scarring in mice. The study is entitled “Identification and isolation of a dermal lineage with intrinsic fibrogenic potential” and was conducted by…

Accurately determining functional impairment of the respiratory system of scleroderma patients is essential to helping their recovery from symptoms. It is especially important to scleroderma patients with interstitial lung disease and pulmonary arterial hypertension associated with their scleroderma, as their lung function is typically much worse than unaffected scleroderma patients.

Fatigue defined as “profound,” “debilitating,” and “preventing autoimmune disease (AD) patients from doing routine tasks. Fatigue affects patients’ mental and emotional well-being and their ability to work. And while most patients with autoimmune disease often discussed their fatigue with their physicians, many have not been prescribed treatment for the symptom. These were…

Researchers at the University of Colorado Boulder and Tsinghua University in China recently published in the journal Science Advances that a specific small molecule is capable of triggering an immune response, having potential biomedical applications for treating diseases such as Scleroderma. The study is entitled “…

In a new study entitled “Subclinical atherosclerosis and peripheral vascular disease in systemic sclerosis patients: Relation to potential risk factors,” authors suggest that patients with Systemic sclerosis may have increased risk of developing subclinical atherosclerotic macro vascular disease. The team highlights that further research is necessary to tackle both…

A new clinical trial on Systemic Sclerosis (also known as Scleroderma) is now recruiting participants – adult patients (at least 18 years old) with a confirmed diagnosis of systemic sclerosis (SSc), as defined by the American College of Rheumatology criteria — who are willing to participate (the study…

In a recent study published in the journal Arthritis Research & Therapy, a research team from the Yonsei University College of Medicine in Seoul, South Korea found that patients with Raynaud’s phenomenon (RP) met 2013 American College of Rheumatology/European League Against Rheumatism criteria for systemic sclerosis…